Drug Approval | November 14, 2022
Stelis receives recommendation from EMA granting market authorization for Kauliv
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Transformation to pure-play Innovative Medicines company nears completion
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Subscribe To Our Newsletter & Stay Updated
